Bladder sparing: Risk-enabled therapy after initiating ...
RETAIN, a phase II trial at GU ASCO 2023, tested sparing cystectomy in muscle-invasive bladder cancer patients with excellent neoadjuvant chemotherapy response. Despite not meeting the primary endpoint of 64% two-year metastasis-free survival (achieved 72%), 46% on surveillance retained their bladder. Findings suggest aggressive treatment for local recurrences and highlight the need for better patient selection in future trials.
Reference News
RETAIN, a phase II trial at GU ASCO 2023, tested sparing cystectomy in muscle-invasive bladder cancer patients with excellent neoadjuvant chemotherapy response. Despite not meeting the primary endpoint of 64% two-year metastasis-free survival (achieved 72%), 46% on surveillance retained their bladder. Findings suggest aggressive treatment for local recurrences and highlight the need for better patient selection in future trials.